Due process: GMP translation and manufacture

Shortening upstream and downstream process is key to cost and natural resource savings and efficiencies for ATMPs. Can we share knowledge for the greater good of patients and the planet?


SIMON PEGG |Director | Project-Ion


NAZNEEN RAHMAN | Founder and Chief Executive Officer | YewMaker
JASON DOWD | Vice-President of Science & Technology | CCRM
WILLIAM ‘BILL’ SCOTT | Scientific Director, Transplant Regenerative Medicine | Newcastle University Medical School
STEVEN TAIT | Business Manager | LifeArc
HARVEY BRANTON | Technology Lead | CPI Biologics